AstraZeneca's Lynparza-Imfinzi combo hits primary endpoint in PhIII endometrial cancer trial DUO-E
AstraZeneca’s blockbuster cancer drugs Imfinzi and Lynparza are stepping into a new indication — first-line endometrial cancer — and significantly improved one of the dual primary endpoints, progression-free survival, when combined with chemotherapy, the company announced Friday.
Detailed data weren’t included in this week’s high-level results from the DUO-E Phase III trial, but AstraZeneca says an Imfinzi-chemo combo followed up with either Imfinzi plus Lynparza or Imfinzi alone as a maintenance therapy both showed a statistically significant and clinically meaningful improvement compared to platinum-based chemo alone in patients with newly-diagnosed advanced or recurrent endometrial cancer.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters